Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal.

Gupta SK, Kizilbash SH, Daniels DJ, Sarkaria JN.

Front Oncol. 2019 Nov 12;9:1216. doi: 10.3389/fonc.2019.01216. eCollection 2019. No abstract available.

2.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
3.

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.

Lin GL, Nagaraja S, Filbin MG, SuvĂ  ML, Vogel H, Monje M.

Acta Neuropathol Commun. 2018 Jun 28;6(1):51. doi: 10.1186/s40478-018-0553-x.

4.

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.

Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ.

Acta Neuropathol Commun. 2014 Jun 3;2:59. doi: 10.1186/2051-5960-2-59.

5.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

6.

Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment.

Zhou Z, Singh R, Souweidane MM.

Curr Neuropharmacol. 2017;15(1):116-128.

7.

Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

Gwak HS, Park HJ.

Crit Rev Oncol Hematol. 2017 Dec;120:111-119. doi: 10.1016/j.critrevonc.2017.10.013. Epub 2017 Oct 31. Review.

PMID:
29198324
8.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
9.

Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma.

Hashizume R.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):331-342. doi: 10.2176/nmc.ra.2017-0018. Epub 2017 Jun 7. Review.

10.

DIPG in Children - What Can We Learn from the Past?

Vanan MI, Eisenstat DD.

Front Oncol. 2015 Oct 21;5:237. doi: 10.3389/fonc.2015.00237. eCollection 2015. Review.

11.

Genomic Insights into Diffuse Intrinsic Pontine Glioma.

Lapin DH, Tsoli M, Ziegler DS.

Front Oncol. 2017 Mar 28;7:57. doi: 10.3389/fonc.2017.00057. eCollection 2017. Review.

12.

Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.

Heiss JD, Jamshidi A, Shah S, Martin S, Wolters PL, Argersinger DP, Warren KE, Lonser RR.

J Neurosurg Pediatr. 2018 Dec 7;23(3):333-342. doi: 10.3171/2018.9.PEDS17225.

PMID:
30544335
14.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
15.

Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.

Meel MH, Sewing ACP, Waranecki P, Metselaar DS, Wedekind LE, Koster J, van Vuurden DG, Kaspers GJL, Hulleman E.

Exp Cell Res. 2017 Nov 15;360(2):397-403. doi: 10.1016/j.yexcr.2017.09.032. Epub 2017 Sep 22.

PMID:
28947132
16.

Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.

Long W, Yi Y, Chen S, Cao Q, Zhao W, Liu Q.

Front Pharmacol. 2017 Jul 25;8:495. doi: 10.3389/fphar.2017.00495. eCollection 2017. Review.

17.

Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.

Tsoli M, Liu J, Franshaw L, Shen H, Cheng C, Jung M, Joshi S, Ehteda A, Khan A, Montero-Carcabosso A, Dilda PJ, Hogg P, Ziegler DS.

Oncotarget. 2018 Jan 8;9(7):7541-7556. doi: 10.18632/oncotarget.24045. eCollection 2018 Jan 26.

18.

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma.

Buczkowicz P, Hawkins C.

Front Oncol. 2015 Jun 30;5:147. doi: 10.3389/fonc.2015.00147. eCollection 2015. Review.

19.

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.

Vitanza NA, Monje M.

Curr Treat Options Neurol. 2019 Jul 10;21(8):37. doi: 10.1007/s11940-019-0577-y. Review.

PMID:
31290035
20.

In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E.

PLoS One. 2013 Apr 29;8(4):e61512. doi: 10.1371/journal.pone.0061512. Print 2013.

Supplemental Content

Support Center